Skip to main content

Table 4 Genetic and laboratory characteristics of the patients regarding the detection of fractures as well as neurological complications (during the second assessment)

From: COL1A1 polymorphism and neurological complications in pediatric acute lymphoblastic leukemia patients and their associations with altered bone mineral density

  Fractures p value Neurological complications p value
+ve (n = 7) −ve (n = 93) +ve (n = 24) −ve (76)
COLIA1genotypes G/G (n = 55) 0 55 (59%) 0.01* 13 (54%) 42 (55%) 0.68
G/T (n = 34) 1 (15%) 33 (35%) 8 (33%) 26 (34%)
T/T (n = 11) 6 (85%) 5 (5%) 3 (12%) 8 (11%)
BMDLS − 2.00 ± 0.44 − 1.00 ± 0.11 0.04* − 2.11 ± 0.41 − 1.10 ± 0.01 0.02*
PTH (ng/l), median (range) 50 (15–59) 49 (12–56) 0.5 48 (20–50) 51 (16–56) 0.9
Vitamin D (nmol/l), median (range) 19 (12–20) 20 (13–35) 0.2 19 (14–35) 20 (15–34) 0.2
OC (ng/ml), median (range) 8 (8–12) 13 (9–20) 0.02* 10 (8–20) 18 (10–19) 0.01*
ALP (U/L), median (range) 45 (45–87) 76 (50–84) 0.03* 50 (45–80) 80 (46–88) 0.01*
  1. *Significant
  2. BMDLS bone mineral density of lumbar spine, PTH parathormon, OC osteocalcin, ALP alkaline phosphatase